Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?
By the Top Tier Newswire AI Desk · September 16, 2026 at 9:33 AM ET · reviewed against 3 wire stories
TWIST BIOSCIENCE COR (TWST) is up +5.95% in the latest session. Our newswire has captured 3 stories on TWST across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
TWST stock rose 5.95 percent to $146.32 in early trading on Monday driven by news of a new collaboration with Lilly TuneLab and updated expectations factoring in pilot work with Anthropic. The stock opened with a modest 0.8 percent gap up and reached a session high of $147.20 before closing near its peak. The stock has surged to a fresh 52-week high as part of a broader upward trend.
What Happened
Twist Bioscience announced a new agreement with Lilly TuneLab to provide antibody characterization data services. This collaboration includes supporting AbLab, an antibody developability prediction model. The partnership aims to integrate artificial intelligence with wet-lab data to advance antibody drug discovery. In addition, the company indicated that pilot work with Anthropic has influenced its expectations for orders in fiscal year 2027. These developments have sparked investor interest and contributed to the sharp rise in the stock price.
What The Data Shows
The stock opened at $139.23 and climbed steadily through the session. It reached a high of $147.20 at 9:30 AM ET and closed near that level at $147.03. The volume was 0.0M shares, which is 0.0 times the 3-month average. Over the past 8 sessions, TWST has gained 5.3 percent, moving from $129.55 to $136.43. Recent insider transactions show three sales totaling $45.4 million in the last 90 days, with the most recent filing on September 10. The stock has also printed two fresh 52-week highs on September 16.
What To Watch
The company has not scheduled earnings for the near term but will likely face continued coverage from analysts and investors following the recent partnership and guidance update. Broader market reactions to biotech sector news may also influence TWST’s near-term performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TWST · today's session (5-min) · +5.09% vs prior close · updated 2:45 PM ETAI sentiment, last 36h · averaged over 3 stories · 64/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoMarketChameleonBULLISH 67Product/PR
Twist Bioscience Ties TuneLab AI Access to Wet-Lab Antibody Data in New Lilly Agreement
September 16, 2026
Twist Bioscience (TWST) announced an agreement to provide antibody characterization data services to Lilly TuneLab, including supporting AbLab, an antibody developability prediction model. The collaboration aims to link Twist’s wet-lab data generation—ordered through TuneLab preferred protocols—to AI/ML-driven candidate down-selection and federated model training.
7h agoStockTitanBULLISH 63Product/PR
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
1d agoThe FlyBULLISH 63Product/PR
Twist Bioscience says Anthropic pilot work factored in FY27 orders expectations
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →